Summary

Glenmark Pharmaceuticals announced strong financial results for the fourth quarter and full fiscal year ended March 31, 2026. Consolidated revenue for Q4 FY26 increased by 15.8% year-on-year to INR 37,706 million, while full-year FY26 revenue grew 27.5% year-on-year to INR 169,825 million. The company reported a Q4 FY26 Profit After Tax (PAT) of INR 3,013 million with a PAT margin of 7.6%, and an FY26 PAT of INR 13,620 million with an EBITDA margin of 26.9%. Chairman & Managing Director, Glenn Saldanha, highlighted FY26 as a 'defining year' for the company, marked by strong business performance and strategic progress, including a landmark AbbVie partnership and expanded differentiated product portfolio.

Key Highlights

1. 1

   Consolidated revenue for Q4 FY26 recorded a significant year-on-year growth of 15.8% to INR 37,706 million.

2. 2

   For the full fiscal year ended March 31, 2026, Glenmark's consolidated revenue surged by 27.5% year-on-year to INR 169,825 million.

3. 3

   Profit After Tax (PAT) for Q4 FY26 was INR 3,013 million, achieving a PAT margin of 7.6% for the quarter.

4. 4

   The full fiscal year FY26 saw PAT reach INR 13,620 million, with an EBITDA margin of 26.9% for the period.

5. 5

   IGI secured a landmark licensing deal with AbbVie for ISB 2001, including a USD 700 million upfront payment and a potential total deal value of USD 1.925 billion.

6. 6

   RYALTRIS® sustained strong global momentum, recording over 50% growth in secondary sales across commercial markets in FY26.

7. 7

   Glenmark's India business delivered robust outperformance, growing at 1.5x the IPM growth and ranking as the 2nd fastest-growing company among the top 15 in FY26.